Japan

Uncategorized

Japan IP High Court 令和3年(ネ)第10037号 (Remitch / 止痒剤) — Extended Pharmaceutical Use Patent Reaches Generic with Same Active Ingredient and Therapeutic Equivalence; ¥21.7 Billion Damages Award Affirmed

The Japan Intellectual Property High Court reversed the Tokyo District Court and held that a generic narlfrafen hydrochloride (nalfurafine) anti-itch product infringes Toray’s term-extended pharmaceutical use patent on Remitch, awarding the patentee approximately ¥21.7 billion (~US$140 million

Scroll to Top